Physician profile
Steven E Mazlin
NPI 1508845504
$2,718.97
in general payments reported to CMS, 2019-2025
35 companies · $23.32 in 2025
The $23.32 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,968 · 2020: $92.61 · 2021: $281 · 2022: $354 · 2025: $23.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $303.56 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $209.53 | 2021-2022 | |
| Acorda Therapeutics, INC | $196.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $166.17 | 2019 | |
| Allergan, INC. | $135.37 | 2019-2021 | |
| Biogen, INC. | $133.34 | 2019 | |
| Avanir Pharmaceuticals, INC. | $114.91 | 2019 | |
| Ucb, INC. | $103.19 | 2019 | |
| Emd Serono, INC. | $102.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $101.25 | 2019 | |
| Amneal Pharmaceuticals LLC | $99.66 | 2019 | |
| Eisai INC. | $88.01 | 2019 | |
| Lilly USA, LLC | $87.04 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $85.38 | 2019 | |
| Genzyme Corporation | $82.63 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.70 | 2019 | |
| Zyla Life Sciences, INC. | $63.91 | 2019 | |
| Mallinckrodt Enterprises LLC | $60.98 | 2019 | |
| Sunovion Pharmaceuticals INC. | $55.74 | 2019 | |
| Upsher-Smith Laboratories LLC | $52.27 | 2019 | |
| Promius Pharma LLC | $42.98 | 2019 | |
| Acadia Pharmaceuticals INC | $38.88 | 2019 | |
| Genentech USA, INC. | $36.83 | 2020-2021 | |
| Depuy Synthes Sales INC. | $34.87 | 2019 | |
| Tersera Therapeutics LLC | $31.72 | 2019 | |
| Merz North America, INC. | $30.10 | 2019 | |
| Mdd US Operations, LLC | $28.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.81 | 2022 | |
| Aquestive Therapeutics, INC. | $23.86 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.23 | 2019 | |
| Lundbeck LLC | $18.98 | 2021 | |
| Iroko Pharmaceuticals, LLC | $15.96 | 2019 | |
| Adamas Pharmaceuticals, INC. | $12.39 | 2021 | |
| Celgene Corporation | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mazlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.